Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention

AI Briefing

• – Medicus Pharma submits optimized Phase 2 study protocol to FDA for Teverelix in treating acute urinary retention
• – Study design aims to detect clear pharmacodynamic signal and generate decision-grade clinical evidence
• – Study to evaluate Teverelix's effectiveness in preventing recurrent acute urinary retention in men with benign prostatic hyperplasia